Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended
		May 13, 2024	Feb. 22, 2024	Jan. 31, 2024	Mar. 31, 2024		Mar. 31, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding					66,720
Proceeds from common stock					$ 786		$ 557
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance					300,001
Increase in available for grant					139,863
Number of common stock purchased					34,332		38,216
Proceeds from common stock					$ 62		$ 182
Treasury stock							12,590
Increase in reserve stock				166,667
Employee Stock Purchase Plan [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance					1,500,000
Increase in available for grant					395,886
Number of common stock purchased					511,884		231,987
Proceeds from common stock					$ 353		$ 276
Increase in reserve stock				500,000
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance					1,835,970
Increase in available for grant				432,452	68,495
Number of stock options outstanding					1,243,933	[1]		1,192,458
Granted	[2]				74,500
Weighted average fair value of stock options					$ 1.46		$ 5.25
2014 Equity Plan [Member] | Parent Company [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted			59,500
Weighted average exercise price			$ 1.85
2014 Equity Plan [Member] | Parent Company [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted			390,000
Aggregate fair value			$ 700
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding					8,332,713	[3]		5,504,383
Granted	[4]				3,000,000
Weighted average fair value of stock options					$ 0.84		$ 0.87
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance					14,324,038
Increase in available for grant				2,680,038	2,680,508
Granted			2,895,000		423,300
Weighted average exercise price			$ 1.25
Number of restricted stock awards granted, shares					50,000
2018 Equity Plan [Member] | Restricted Stock [Member] | Lucid Diagnostics Inc [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted		1,600,000
Aggregate fair value		$ 1,500

[1] The outstanding stock options presented in the table above are inclusive of 60,054 stock options granted outside the PAVmed 2014 Equity Plan, as of March 31, 2024 and December 31, 2023.

[2] Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.

[3] The outstanding stock options presented in the table above are inclusive of 423,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of March 31, 2024 and December 31, 2023.

[4] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.